Zobrazeno 1 - 10 of 13 pro vyhledávání: '"Yiran B Hu"'
1
TURQUOISE-I Part 1b: Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin for Hepatitis C Virus Infection in HIV-1 Coinfected Patients on Darunavir
Autor: Jacob Lalezari, Amit Khatri, Peter Ruane, Jennifer R. King, Rolando M Viani, Michael S. Saag, Laveeza Bhatti, Roger Trinh, Oluwatoyin Adeyemi, David L. Wyles, Nancy S. Shulman, Yiran B Hu
Publikováno v: The Journal of Infectious Diseases. 215:599-605
Background Ombitasvir/paritaprevir/ritonavir with dasabuvir (OBV/PTV/r + DSV) ± ribavirin (RBV) is approved for hepatitis C virus (HCV) genotype 1 (GT1) treatment in HIV-1 coinfected patients. In healthy controls, coadministration of OBV/PTV/r + DSV
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e7062c0af27e2ba1f3430de88c7aac6f
https://doi.org/10.1093/infdis/jiw597
Zobrazit plný text záznamu
3
Safety and Efficacy of Ombitasvir, Paritaprevir With Ritonavir ± Dasabuvir With or Without Ribavirin in Patients With Human Immunodeficiency Virus-1 and Hepatitis C Virus Genotype 1 or Genotype 4 Coinfection: TURQUOISE-I Part 2
Autor: Rolando M Viani, Roger Trinh, Giuliano Rizzardini, Cristina Tural, Pierre-Marie Girard, Yiran B Hu, N. Mobashery, Hartwig H F Klinker, Linda M Fredrick, Edward Gane, Chloe Orkin, Nancy S. Shulman, David L. Wyles, Tami Pilot-Matias, Adriano Lazzarin, Jürgen K. Rockstroh, Sanjay Bhagani, Mark Nelson, Ruth Soto-Malave, Anne F Luetkemeyer
Publikováno v: Open Forum Infectious Diseases
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Background Ombitasvir, paritaprevir with ritonavir, and dasabuvir (OBV/PTV/r ± DSV) ±ribavirin (RBV) are approved to treat hepatitis C virus (HCV) genotype 1 and 4 infection. Here, we investigate the safety and efficacy of OBV/PTV/r + DSV ±RBV for
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c6961fa3ddec3fa06f99a2c4235b26e1
https://doi.org/10.1093/ofid/ofx154
Zobrazit plný text záznamu
4
1979. Time to Viral Suppression Does Not Impact SVR in Patients Treated With Glecaprevir/Pibrentasvir for 8 Weeks
Autor: Federico J. Mensa, David W. Victor, Sanjeev Arora, Christoph Sarrazin, Stanley Wang, Douglas E. Dylla, Jordan J. Feld, David L. Wyles, Tram Tran, Yiran B Hu
Publikováno v: Open Forum Infectious Diseases
Background The pangenotypic direct-acting antivirals (DAAs) glecaprevir (developed by AbbVie and Enanta) coformulated with pibrentasvir (G/P) are approved as an 8-week regimen to treat chronic HCV infection for all six major genotypes (GT). An integr
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5d8d889de964fc62e5935a6b18d9a23
https://doi.org/10.1093/ofid/ofy210.1635
Zobrazit plný text záznamu
6
ABT-450, Ritonavir, Ombitasvir, and Dasabuvir Achieves 97% and 100% Sustained Virologic Response With or Without Ribavirin in Treatment-Experienced Patients With HCV Genotype 1b Infection
Autor: Iftihar Koksal, Peter Ferenci, B. Bernstein, Beat Müllhaupt, Jeffrey Enejosa, Yiran B Hu, Lino Rodrigues, Pietro Andreone, Massimo Colombo, Andreas Maieron, Ola Weiland, Henk W. Reesink, Thomas Podsadecki, Yves Horsmans
Publikováno v: Gastroenterology, Vol. 147, no. 2, p. 359-365.e1 (2014)
Gastroenterology, 147(2), 359-365.e1. W.B. Saunders Ltd
BACKGROUND & AIMS: The interferon-free regimen of ABT-450 (a protease inhibitor), ritonavir, ombitasvir (an NS5A inhibitor), dasabuvir (a non-nucleoside polymerase inhibitor), and ribavirin has shown efficacy in patients with hepatitis C virus (HCV)
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ca572d92865c388d1860f033e7959c3
https://hdl.handle.net/11380/1237124
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje